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Abstract
Modern pharmaceutical industries have faced significant challenges to deliver safe and
effective medicines because of significant toxicity and severe side effects of discovered
drugs. On the other hand, recent developments and advances in system-based pharma-
cology aim to address these challenges. In this chapter, we provide an overview of
quantitative methods for system-based drug discovery. System-based drug discovery
integrates chemical, molecular, and systematic information and applies this knowledge
to the designing of small molecules with controlled toxicity and minimized side effects.
First, we discuss current approaches for drug discovery and outline their advantages and
disadvantages. Next, we introduce basic concepts of systems pharmacology with an
emphasis on ligand-based drug discovery and target identification. This is followed by a
discussion on structure-based drug design and statistical  tools  for  pharmaceutical
research. Finally, we provide an overview of future directions in systems pharmacology
that will guide further developments.
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1. Introduction
The discovery of effective medicines has been a long-term human endeavor aimed at curing
illnesses and improving physiological conditions. Early drug discovery methods often relied
on  serendipitous  findings.  For  example,  penicillin,  a  substance  released  by  mold,  was
accidentally discovered to inhibit bacterial growth. However, with the advances of molecular
cloning techniques,  X-ray crystallography,  robotics,  and computational  aided technology,
drugs can now be rationally designed. Additionally, the marriage of combinatorial chemistry
and  robotics  has  also  created  a  new  drug  discovery  approach  called  “high-throughput
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screening.” In a high-throughput screening campaign,  a  library consisting of  millions of
molecules is tested against a disease-relevant target to identify potential drug candidates.
However, the application of modern drug discovery methods has not directly translated into
increases in the output of new drugs. Although many of these “designer” drugs have been
optimized for binding and specificity, they are all low-weight molecular ligands and are likely
to interact with multiple off-targets, which contribute to severe side effects in patients taking
these medicines. Consequently, a system drug discovery approach that simultaneously
optimizes drug binding, target promiscuity, and safety profile has been proposed. In particular,
“poly-pharmacology” is a new drug discovery paradigm that aims to study the interactions
of many drugs to many targets as many body problems. The binding profile of a compound
can be used to modify a ligand structure to maximize on-target binding while minimizing off-
target interactions. More recently, “structural poly-pharmacology” has also been proposed,
which utilizes the structural data of proteins or drugs to gain a mechanistic understanding of
drug action and side effects [1, 2].
System-based drug discovery can be classified as ligand-based and structure-based drug
discovery approaches. In the ligand-based drug discovery approach, ligand structure infor-
mation takes center stage, and only ligand information is used to derive its multitude of
chemical and biological properties. On the other hand, the structure-based approach utilizes
the structure of the receptor to identify shape-complementary ligands with optimal interac-
tions. Given a validated disease target with a known crystal structure, the structure-based
approach can be utilized to discover ligands that bind to the receptor of interest. On the other
hand, the ligand-based approach is useful when the target structure is unknown or when the
crystal structure of the target is difficult to obtain. In some cases, the system-based drug
discovery approach combines both ligand-based and structure-based approaches to facilitate
the drug design and discovery process [3].
2. Ligand-based approaches to drug design
2.1. Introduction
Ligand-based drug design, also known as “knowledge-based” drug design, extracts essential
chemical features from drugs to construct a learning model to predict drug properties. It has
been proposed that a ligand structure contains all the necessary information to accurately infer
its mechanism of action. Several chemical descriptors such as molecular weight and lipophi-
licity are predictors of important pharmacodynamic and pharmacokinetic properties of
ligands. A well-known example is Lipinski’s rule of five, which describes a set of chemical
properties and rules that can be used to differentiate drugs from nondrug molecules [4].
Likewise, the chemical similarity principle has been widely applied in similarity-based drug
design. The chemical similarity principle assumes that if two molecules share similar struc-
tures, then they will likely have similar biological properties [5]. This concept is the underlying
principle of modern chemical database search techniques used to identify similar compounds
with improved bioactivities.
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2.2. Outline of ligand-based drug design
The chemical similarity search is an established approach for ligand-based drug discovery.
Given a compound with known biological properties, it is possible for a drug designer to
identify similar compounds with improved biological properties. To compare two ligand
structures, it is essential to develop appropriate data structure representations for chemical
structure comparisons. Mathematically, the chemical structure can be represented by graphs
where atoms represent vertices and edges represent chemical bonds [6]. Several chemoinfor-
matics algorithm can be used to extract essential characteristic from the chemical graph such
as the number of vertices, the number of bonds, path, connectivity, and others. These properties
then become chemical features that can be used in feature engineering using complex machine
learning techniques for similarity comparison.
The most direct chemical search approach is the nearest neighbor where the chemical feature
of a ligand, also known as a “chemical fingerprint,” is used to search a compound database to
identify the most similar compounds using a predefined distance measure [7]. The most
commonly used chemical fingerprints include path-based and substructure-based finger-
prints. Using path-based fingerprints, such as Daylight fingerprints or Obabel FP2 fingerprints,
potential paths at different bond lengths in a molecular graph of a molecule are used as features
for the similarity comparison. On the other hand, substructure-based fingerprints such as
MACCS keys use predefined substructures and characterize each molecule based on the
presence or absence of a particular substructure using a binary array. Overall, path-based
fingerprints offer higher search specificity due to the unique path dependency of the molecular
graph. However, substructure-based fingerprints can be used to identify scaffold hopping
ligands since the fingerprints do not impose requirements on the connectivity of the scaffolds
and functional groups [8]. To quantify the chemical similarity between two fingerprints, several
distance metrics have been proposed. The most commonly used chemical similarity metric is
the Tanimoto index, which computes the shared feature bits between two fingerprints in the
range of 0–1. Although there is no predefined threshold to define the similarity level, a value
of 0.7–0.8 has been commonly adapted in many chemical similarity search programs.
2.3. Ligand-based drug design (LBDD) process
The similarity-based drug design process is as follows (Figure 1):
1. The target molecule is used as a query for the chemical search.
2. Similar ligands with similar biological properties are identified.
3. Original ligands are modified to suggest new molecules with improved activities.
The advantages of LBDD are as follows:
1. Does not necessitate receptor structures.
2. Low computational intensity and fast database searching.
3. Allows for large-scale similarity drug design and target prediction.
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Figure 1. Ligand-based drug design (LBDD) process.
2.4. Target prediction of drugs
While similarity-based methods are prevalently applied in modern drug discovery programs
as an efficient way to transition a hit to a lead, the molecular mechanism of the drug is often
unknown, and the adverse reaction cannot be predicted. Consequently, drug-target prediction
becomes an important follow-up step. Drug-target prediction can be classified as ligand-based
or structure-based methods [9]. In ligand-based target prediction, the molecular target of a
drug can be inferred from the target-annotated ligand sharing the highest chemical similarity.
Chemical bioactivity databases such as ChEMBL, PubChem and DrugBank, and BindingDB
have been developed for this application [10]. However, one major limitation of ligand-based
target prediction is that there is no natural cutoff for chemical similarity that clearly defines
biological similarity, also known as bioactivity cliffs. Approaches such as similarity ensemble
approach (SEA) aim to remedy this by calculating similarity values against a random back-
ground using an algorithm similar to BLAST [11]. On the other hand, structure-based target
prediction methods identify molecular targets based on the structure of the receptor binding
sites. For example, panel docking is a common structure-based approach to identify the most
probable target based on the docking score. Alternatively, binding site similarity methods that
compare the receptor environment of the target ligand to a database of receptor pockets have
also proven to be an effective target prediction approach [12].
More recently, network poly-pharmacology has been proposed as a more comprehensive
approach to analyze drug-target interactions. Network pharmacology goes beyond the one
drug one target hypothesis to multiple drugs multiple targets hypothesis [13]. The goal of this
new paradigm is not only to accurately identify on-targets but also other off-targets. One such
approach is the drug-target network, which utilizes a bipartite network to analyze complex
drug gene interactions. Alternatively, drug-drug networks or chemical similarity networks
have also been proposed [8]. The chemical similarity network clusters drugs based on their
structure similarity. This approach can be applied for large-scale compound analysis by
clustering diverse chemical structures into distinct scaffolds known as chemotypes. Conse-
quently, each chemotype can be correlated with specific molecular targets. Using a consensus
statistics scheme similar to that used for functional prediction in protein-protein interaction
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networks, chemical similarity networks have proven useful for target identification from
chemical screening campaigns. In addition, structural poly-pharmacology has also gained
substantial attention due to the possibility of correlating structural variations to clinical side
effects. One example is CSNAP3D, which uses 3D ligand structure similarity to identify
simplified scaffold hopping compounds of complex natural products to suggest new drugs
with improved pharmacokinetic properties [1].
2.5. Side effect prediction of drugs
Since severe clinical side effects have contributed to drug failure in the late stages of clinical
trials, side effect prediction will need to become an integrated part of the drug design process.
Knowing the binding affinity of a drug to an array of proteins makes it possible to predict side
effects using several statistical methods such as canonical component analysis (CCA), which
identify a set of parameters that optimize the correlation between drug binding features and
side effect features [14]. In addition, side effect predictions based on chemoinformatics analysis
of the compound structures have also been developed. Many of these approaches provide an
accurate prediction of the drug side effects and have been applied in the early stages of clinical
drug development.
3. Structure-based approaches to drug design
Modern medicinal chemistry methods and molecular modeling have been employed as
powerful tools for the study of structure-activity relationships (SAR) [15]. Structure-based
drug design is a drug discovery approach by which synthetic compounds are designed from
detailed structural knowledge of the active sites of protein targets associated with particular
diseases. This field has involved the integrated application of traditional biology and medicinal
chemistry along with advances in biomolecular spectroscopic methods such as X-ray crystal-
lography, nuclear magnetic resonance (NMR), combinatorial chemistry, computer modeling
of molecular structure, and protein biophysical chemistry, to focus on the three-dimensional
molecular structure and active site characterization of the proteins that control cellular biology.
Structure-based drug design is an improvement over traditional drug screening techniques.
By identifying the target protein in advance and by discovering the chemical and molecular
structure of the protein, it is possible to design a more optimal drug to interact with the protein.
3.1. Basic concept of structure-based drug design
Enzymes are a subset of receptor-like proteins that are directly responsible for catalyzing the
biochemical reactions that sustain life. For example, digestive enzymes act to break down the
nutrients of our diet. DNA polymerase and related enzymes are crucial for cell division and
replication. Enzymes are genetically programmed to be specific for their appropriate molecular
targets. Any errors could have grave consequences. Enzymes ensure the specificity of their
targets by forming a molecular environment that excludes interactions with inappropriate
molecules. The analogy most often mentioned is that of a lock and key. The enzyme is a
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molecular lock, which contains a keyhole that exhibits a very specific and consistent size and
shape. This molecular keyhole is termed the active site of the enzyme and allows interaction
with only the appropriate molecular targets. Just as a typical lock is much bigger than the
keyhole, the receptor is usually much larger than the active site. The receptor, as specified by
our DNA, is a folded protein whose major purpose is to form and maintain the size and shape
of the active site.
The most important concept in drug design is to understand the methods by which the active
site of the receptor selectivity restricts the binding of inappropriate structures. Any potential
molecules that can bind to a receptor are called ligands. In order for a ligand to bind, it must
contain a specific combination of atoms that present the correct size, shape, and charge
composition needed to bind and interact with the receptor. In brief, the ligand must possess
the molecular key that binds the receptor lock.
Computer-aided drug design has played an important role in drug discovery and drug
development and has become an indispensable tool in the drug industry. For the purposes of
discovering and optimizing biologically active compounds, various types of computer-aided
drug design software and resources have been used by computational medicinal chemists.
Unsurprisingly, many chemical compounds were discovered and optimized by computer-
aided drug design methodologies and have reached the late stages of clinical trials.
3.2. Outline of structure-based drug design
Structure-based drug design is a cyclic process which consists of stepwise procedures
(Figure 2). It begins with a known target structure, and then, in silico studies are conducted
in order to identify potential ligands. These molecular modeling procedures are followed
by the synthesis of the most promising compounds [16]. Next, using diverse experimental
platforms, biological properties such as potency, affinity, and efficacy are evaluated [17]. In
the end, given that active compounds are identified, the three-dimensional structure of the
ligand-receptor complex can be solved. The available structure allows the visualization of
the intermolecular features that support the process of molecular recognition. Structural
descriptions of ligand-receptor complexes are useful for the investigation of binding
conformations, characterization of key intermolecular interactions, characterization of
unknown binding sites, mechanistic studies, and the elucidation of ligand-induced confor-
mational changes [18].
3.3. Process of structure-based drug design (SBDD)
The structure-based drug design process is as follows:
1. An enzyme that is important in a particular pathological condition is chosen.
2. The three-dimensional structure of the active site of the enzyme is determined, often by
X-ray crystallography.
3. A chemical is prepared to fit the active site of the enzyme, which can alter the properties
of the enzyme, that is, inactivate the enzyme.
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The advantages of structure-based drug design are as follows:
1. Useful results are obtained faster than by traditional drug design methods.
2. The process is less expensive than other drug design methods.
3. The compounds are more specific for the active site and potentially less toxic than
compounds prepared by other approaches.
Figure 2. Structure-based drug design (SBDD) process.
3.4. Synthesis of lead compound
The initial drug design phase is followed by the synthesis of the lead compound, quantitative
measurements of its ability to interact with the target protein, and X-ray crystallographic
analysis of the compound-target complex. This analysis reveals important, empirical infor-
mation on how the compound actually binds to the target, and the nature and extent of changes
induced in the target by the binding. These data, in turn, suggest ways to refine the lead
compound to improve its binding to the target protein. The refined lead compound is then
synthesized and complexed with the target, and further refined in a reiterative process. If lead
compounds are available from other studies, such as screening of combinatorial libraries, these
compounds may serve as starting points for this optimization cycle using structure-based drug
design.
Once a sufficiently potent compound has been designed and optimized, its activity is evaluated
in a biological system to establish the compound’s ability to function in a physiological
environment. If the compound fails at any stage of the biological evaluation, the design team
reviews the structural model and uses crystallography to adjust structural features of the
compound to overcome the difficulty. This process continues until a designed compound
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exhibits the desired properties. The compound is then evaluated in an experimental disease
model. If the compound fails, the reasons for failure (e.g., adverse metabolism, plasma binding,
distribution, etc.) are determined, and again new modified compounds are designed to
overcome the deficiencies without interfering with their ability to interact with the active site
of the target protein. The experimental drug is then ready for conventional drug development
(e.g., studies in safety assessment, formulation, clinical trials, etc.). This reiterative analysis and
compound modification are possible because of the structural data obtained by X-ray crystal-
lographic analysis at each stage. This capability renders structure-based drug design, a
powerful tool for rapid and efficient development of drugs that are highly specific for particular
protein target sites.
3.5. Docking methodologies
Several docking procedures exist in the literature, from the use of interactive graphics to
manipulate the position of the ligand to completely automated procedures, which are becom-
ing increasingly powerful to screen databases of molecules. Many docking algorithms follow
a similar pattern. Usually, the first stage is to represent the molecules by their solvent-accessible
surfaces. Beginning with a number of different relative orientations, the two molecules can
then be brought together. More sophisticated methods carry out their moves by using a Monte
Carlo algorithm to direct both rotations and translations. Rapid convergence to a minimum
can be achieved by gradually cooling the simulation temperature as the molecule appears to
be descending into a potential well.
Figure 3. The molecular docking methodology. (A) Prepare the ligand structure, (B) Prepare the receptor structure, (C)
Dock the ligand into the receptor surface with multiple potential conformations. (D) The most likely binding mode was
identified based on intermolecular interaction between the ligand and the receptor surface. The protein backbone is
represented as a cartoon. The ligand and active site residue are shown in stick representation.
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Molecular docking is one of the most frequently used methods in structure-based drug design
because of its ability to predict, with a substantial degree of accuracy, the conformation of
small-molecule ligands within the appropriate target binding site (Figure 3) [19]. Following
the development of the first algorithms in the 1980s, molecular docking became an essential
tool in drug discovery [20]. Highly intensive investigations involving crucial molecular events,
including ligand-binding modes and the corresponding intermolecular interactions which
stabilize the ligand-receptor complex, could be conveniently performed. Furthermore,
molecular docking algorithms execute quantitative predictions of binding energetics, given
docked compounds, based on the binding affinity of ligand-receptor complexes [21].
3.6. Computer simulation in drug design
The development of a new drug starts with the design of suitable candidate compounds so-
called “ligands” that are selected according to observations about how these compounds are
recognized by the target protein and how they bind to it. It is important to know that proteins
have dynamic properties: they change their shape in much the way as a machine tool needs to
in order to fulfill its function. Now, it is being realized how important it is to have techniques
available for studying protein dynamics. Performing experiments is not only expensive but
also very time-consuming and, moreover, cannot answer all relevant questions. An alternative
is computer-aided simulation of the dynamics of molecules [molecular dynamics (MD)
simulations], which is becoming increasingly important to identify the molecular properties
that are important and to determine the detailed molecular interactions that are critical for
binding.
In some instances, high-performance computing (HPC) is required to cross the threshold
where MD simulation becomes a valuable tool for industry. However, in most pharmaceutical
companies, HPC is something very new, and supercomputers are simply not available to
industrial researchers. With the arrival of affordable high-performance multiprocessor
machines and corresponding developments of parallel software, it now becomes possible for
industrial researchers to undertake more realistic calculations that were previously out of
reach. Scientists at Novo Nordisk, a large Danish pharmaceutical company, are convinced that
this new capability will dramatically change the acceptance of MD simulation as a tool in the
design of new ligands. During Europort-D, they, for the first time, studied the dynamics of the
complex molecular interactions critical for recognition of ligands by their target proteins.
4. Statistical tool for drug design
4.1. Introduction to SPASS for pharmaceutical research
As a sophisticated statistical software, Statistical Package for Social Science (SPSS) can help
researchers and users realize their complex statistical tests with result interpretation and the
access to data figures, tables, and graphs, which can be quickly and easily displayed in the
output view. Even though additional training is usually required before users can maximize
its features and the graphing feature is not as simple as an excel spreadsheet, SPSS is still being
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used by more and more researchers from other fields for applications specific to their research
areas, for example, the application of SPSS in clinical trials, with power and sample size
calculation functions, comprehensive statistical tests and graphical tools, such as predictive
data trends, forecasting and report generation, and the analysis of complex drug assays, etc.
[22].
SPSS is being used majorly in pharmaceutical and medical research, where it can provide
techniques for the design, implementation, and development of drug campaigns that are
important to pharmaceutical research organizations and also provides data mining solutions
based on their existing data on quality control and manufacturing, regulatory safety testing,
clinical trials, data mining in drug discovery, compliance, and validation [23]. As many
pharmaceutical research organizations have experienced that even small improvements in
research or processing affect the efficiency and success of the project, SPSS provides a sophis-
ticated analytical platforms to decrease development costs and unnecessary preclinical and
clinical trials by integrating with existing data sources.
Overall, the tools in SPSS provide an efficient mechanism to automatically validate the routine
analysis reports. In other words, SPSS empowers researchers with tools, which might bring
the rapid and solid return on investments in the near future.
4.2. Outlines of the SPASS package
SPSS is a Windows-based program, which can be used to perform data entry and data analysis
by tables and graphs (Figure 4). Because SPSS is capable of dealing with huge amounts of data
with different modules, it is commonly used in the business world and in the Social Sciences
[24]. Familiarity with this software will be useful in the field of drug research where big data,
Figure 4. SPSS package in pharmaceutical data analytics application.
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such as clinical trials data ranging from simple bioassays and dose-response experiments to
long-term survival, and carcinogenicity studies need to be integrated. Unlike Excel, SPSS
software can support screen transfers between the data entry view and the output view, which
display the results and summarize the data.
4.3. Features of SPSS package
Whether its small and medium enterprises (SME) or large-scale enterprises (LSE), the appli-
cation of SPSS can provide data accessing in rational data sets, which allows accessing inflexible
resources and practices and real-time processing, and mapping of the database [25]. Although
other commercial softwares, such as SAS, MATLAB, and others, can also perform such
functions, SPSS is a more sophisticated application in statistics analysis. SPSS conducts
statistical analysis from basic data, descriptive statistics, such as average and prevalence, and
advanced inferential statistics, such as t test, regression model, one-way and factorial analysis
of variance (ANOVA), one-way and factorial analysis of covariance (ANCOVA), one-way and
factorial multivariate analysis of variance (MANOVA), one-way and factorial multivariate
analysis of covariance (MANCOVA), factor analysis, path analysis, and logistic regression [26].
Normally, researchers use SPSS as a tool to collect and analyze data. The data entry screen in
SPSS looks like an excel spreadsheet, and users can input variables and quantitative data and
save the file as a data file [27]. After data are collected and entered into the data sheet in SPSS,
users can also create an output file from the data they used. Then, the users can edit or organize
the data in SPSS to check the running results after they choose the module they want. For
example, users can check out the frequency distributions of the data to see whether the data
set is normally distributed. Furthermore, the researchers can download the tables or graphs
directly from the data output view. Because SPSS has the statistical tests built-in to the program,
users do not need to do any math calculation or equations to get the results.
5. Conclusion and future direction
Systems pharmacology represents a new paradigm in drug research where ligand and protein
information are combined to produce new methods for drug discovery and design. Tradition-
ally, ligand-based approaches utilize information contained within the chemical structure to
predict the biological properties of the drug. In particular, chemical similarity database
searches can be used to identify molecules with improved activity. However, to be able to
design compounds with satisfactory safety profiles, the drug targets will also need to be
determined. Target prediction can be performed using ligand or structure data. Both of these
approaches require a bioactivity database with pre-characterized activities or functions. If the
target structure of the ligand is known, then the structure-based drug discovery approach can
be applied. Computer-aided drug design techniques such as molecular docking and molecular
dynamic simulation are capable of accurately predicting the binding sites of ligand, docking
pose, and binding affinity based on the geometry of the receptor surface. The prediction can
then be validated using in vitro biochemical assays and X-ray crystallography to validate ligand
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binding. Thus, a cyclic drug design process is then continued until the strongest binder is
found.
Currently, drug discovery has been mainly focused on in vitro optimization. One future
direction in system-based drug discovery will necessarily shift to ADMET prediction to assess
drug performance in vivo. Although several ADMET properties such as drug-likeness can be
predicted by simple rules, a more detailed classification of drug properties can be achieved by
more advanced machine learning techniques. Likewise, a holistic drug design process that
simultaneously optimizes the drug properties based on in vitro and in vivo data will also hold
promise to optimize drug safety and minimize adverse reactions. Consequently, integration
of multilevel data from structure, tissue, and the whole organism will be required to achieve
a more accurate prediction. In conclusion, we have presented the essential quantitative
methods in system-based drug discovery, and the approaches presented here will stimulate
further efforts in the progress of drug discovery and design to engineer safer and more effective
drugs.
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